Boehringer Ingelheim Pharmaceuticals has posted results from the Phase III RE-COVER II study evaluating Pradaxa (dabigatran) compared to warfarin in patients diagnosed with acute deep vein thrombosis (DVT) and/or pulmonary embolism (PE). In this study, dabigatran met the primary endpoint of non-inferiority to warfarin for recurrent, symptomatic, objectively-confirmed DVT and/or PE and related deaths during six months of treatment. DVT and PE are collectively referred to as venous thromboembolis...